Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA427734
Max Phase: Preclinical
Molecular Formula: C13H7ClN6O3
Molecular Weight: 330.69
Molecule Type: Small molecule
Associated Items:
ID: ALA427734
Max Phase: Preclinical
Molecular Formula: C13H7ClN6O3
Molecular Weight: 330.69
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(O)c1cc2c3cc(-n4cnnc4)c(Cl)cc3[nH]c(=O)n2n1
Standard InChI: InChI=1S/C13H7ClN6O3/c14-7-2-8-6(1-11(7)19-4-15-16-5-19)10-3-9(12(21)22)18-20(10)13(23)17-8/h1-5H,(H,17,23)(H,21,22)
Standard InChI Key: CVQAHSMQXIWVLD-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 330.69 | Molecular Weight (Monoisotopic): 330.0268 | AlogP: 1.11 | #Rotatable Bonds: 2 |
Polar Surface Area: 118.17 | Molecular Species: ACID | HBA: 7 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.44 | CX Basic pKa: 1.61 | CX LogP: 0.73 | CX LogD: -2.66 |
Aromatic Rings: 4 | Heavy Atoms: 23 | QED Weighted: 0.57 | Np Likeness Score: -1.27 |
1. Varano F, Catarzi D, Colotta V, Filacchioni G, Galli A, Costagli C, Carlà V.. (2002) Synthesis and biological evaluation of a new set of pyrazolo[1,5-c]quinazoline-2-carboxylates as novel excitatory amino acid antagonists., 45 (5): [PMID:11855983] [10.1021/jm010995b] |
2. Varano F, Catarzi D, Colotta V, Lenzi O, Filacchioni G, Galli A, Costagli C.. (2008) Novel AMPA and kainate receptor antagonists containing the pyrazolo[1,5-c]quinazoline ring system: Synthesis and structure-activity relationships., 16 (5): [PMID:18063372] [10.1016/j.bmc.2007.11.046] |
3. Jiang X, Wu K, Bai R, Zhang P, Zhang Y.. (2022) Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities., 229 [PMID:34998058] [10.1016/j.ejmech.2021.114085] |
4. Haghighijoo Z, Zamani L, Moosavi F, Emami S.. (2022) Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review., 227 [PMID:34742016] [10.1016/j.ejmech.2021.113949] |
Source(1):